Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodiesWilton B. Williams, Barton F. Haynes, Hua-Xin Liao et al.|Science|2015Cited by 202
Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for DeliverySpyros A. Kalams, Scott Parker, Marnie Elizaga et al.|The Journal of Infectious Diseases|2013Cited by 197
The Emperor’s New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE)Thomas P. Lodise, Thomas L Holland, Dannah Wray et al.|Clinical Infectious Diseases|2019Cited by 158
A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)Gavin Churchyard, Cecilia Morgan, Elizabeth M. Adams et al.|PLoS ONE|2011Cited by 137
Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120Nina D. Russell, Lawrence Corey, Barney S. Graham et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2006Cited by 104